Study of a humanized inhibitory anti-platelet glycoprotein Ⅵ single chain fragment variable phage an

• 作 者: XuebinJi;MingHou;
• 机 构: Department of Hematology, QiLu Hospital of Shandong University, Jinan, China PR
• 出 处: 山东省抗癌协会第五次会员代表大会暨山东省第四届肿瘤学术大会
• 发表日期: 2015年期

　　The aims of the study were to study the effect of anti-platelet glycoprotein Ⅵ auto-antibodies on platelet aggregation and use phage surface display technology to produce anti-platelet glycoprotein Ⅵ single chain fragment variable antibody fragment, which may be developed to inhibit platelet aggregation in the treatment of cardiovascular disease in the future.Plasma samples from patients with immune thrombocytopenia (ITP) were screened by monoclonal antibody immobilization of platelet antigen (MAIPA) assay and platelet aggregation test for anti-platelet GPVI auto-antibody with inhibitory effect.The humanized anti-platelet GPVI ScFv was produced by phage surface display technology.The function of the ScFv fragment against platelet aggregation was examined by platelet aggregation test.Of 726 ITP patients, 2 (0.27%) patients' plasma significantly inhibited platelet aggregation induced by collagen-1.After five rounds of selection, enrichment, and purification, a soluble ScFv phage antibody was produced, which can inhibit platelet aggregation induced by collagen-1.The results demonstrate that only a few of the screened anti-platelet GPVI auto-antibodies showed an inhibitory effect on platelet aggregation.The humanized anti-platelet GPVI ScFv antibody fragment produced by phage surface display technology presents promising prospects for inhibiting platelet aggregation in the treatment of cardiovascular disease.